Raymond James Reiterates Outperform Rating for CME Group Ahead of Q2 Earnings

Key Facts

1Raymond James reiterated an Outperform rating for CME Group Inc. with a $320.00 price target ahead of Q2 2026 results.

2CME Group reported record trading volumes for June 2026 and announced new futures and options contracts pending regulatory approval.

As markets anticipate major financial earnings, CME Group stands out due to its dominant position in the derivatives sector. Raymond James has reiterated its Outperform rating for the company with a $320.00 price target ahead of the Q2 2026 earnings release. The group reported record trading volumes in June 2026 and has announced new futures and options contracts that are currently pending regulatory approval.

This bullish outlook comes as the stock trades at an attractive valuation of 18 times 2027 non-GAAP EPS estimates, which analysts view as undervalued. Compared to industry peers, market data shows steady performance for Intercontinental Exchange (ICE) and Nasdaq (NDAQ), reinforcing CME's role as a primary venue for interest rate hedging. Analysts view the recent temporary slowdown in trading volumes as a transient phase that does not undermine the firm's fundamental growth story.

Traders should watch current price levels closely; CME Group (0HR2.L) stood at $228.72 at close July 1, 2026, after hitting a session high of $228.84. Looking ahead, upcoming catalysts include speeches from Fed officials Williams and Kashkari, which may provide insight into interest rate trajectories that directly impact trading volumes in CME's core interest rate products.